Thanksgiving 2019 is here and Denver is covered in a snowstorm. It’s a perfect setting to get the Holidays started, and it’s my favorite time of the year. One of the key reasons I love Thanksgiving is because I like to reflect on the year that has passed and remember the people who have been a part of my life. That’s not to say the year hasn’t had its share of obstacles and adversity, but on balance it’s been terrific.

Since this is a post on our company blog, I will skip the gratitude I have for family. Instead, I want to focus on the friends and colleagues who have contributed to the growing AngelMD community.

AngelMD has an extremely talented and hard-working team. It’s led by Michael Raymer, Steve Foster, Dave Farmer and John Cox. Each is amazing and it’s fun to watch their talent in motion.

We have some incredible new additions to our product team including Taylor Dollarhide and Chris Losacco. They are the most talented product – designer duo I have ever worked with and I can’t wait to see what they release for our members in 2020.

Dave Farmer has begun to assemble a really sharp digital studio team that includes Tyler Patterson and Kelsey Seufer. Their digital magic has already begun to impact our community.

Our engineering staff are diligent day in and day out with the foundation provided by Ryan Stephens and Andrew James. We recently added Ty Hyten and Danielle Mullane and they spent no time starting to contribute.

Brad McCarty is our remote Marketing Director from Nashville and even though he is out of site most of the time, he is very much appreciated across the board for all his talent.

Charles Emley, Jeff Ross MD, Reed Hatch, Andrew Malloy and Paul Schuber anchor our financial operations organization and work closely with Mark Mescher who oversees startup operations. All of them work their tails off and are constantly looking for new ways to improve the community experience and drive stronger investments in the process. Roger Hauptman keeps us on track with his thoughtful approach to General Counsel efforts.

While I would stack this team up against any team, we are all blessed to work with amazing startup entrepreneurs from around the world and physicians who are the underpinning of our medical system. The hard work and dedication of both our entrepreneurial community and physician community is the immediate thing they share in common. None of them know what a scheduled break is and we get to see their work in motion every day. Ultimately, all of them want to improve their part of the healthcare system to better serve patients.

There are a few amazing physicians I want to thank by name as they have been a key part of the AngelMD team: Mark Froimson MD, Wendy Whittington MD, J. Michael Bennett, MD, Fred Duffy MD, Ronnie Mimram MD and Joe Macaluso MD.

Finally, I want to thank some of our strategic partners. Specifically, Catalyst HTI, The American College of Cardiology and Delta Dental of Colorado.

As I reflect on the growing ranks of members and partners dedicated to healthcare innovation and committed to life-long learning, I cannot approach the holidays with anything less than a deep sense of thankfulness.

Continue reading

AngelMD Opens its Healthcare Investment Platform to Dentists

AngelMD is proud to announce that it is expanding its platform to enhance the engagement of its growing dental community. AngelMD is a platform that brings startups, healthcare experts, and investors together to provide better outcomes for patients, startups, and investors alike. Until today, dentists had a less pronounced voice on the network. But the $138 billion oral health market is ripe for innovation, and via AngelMD the nearly 200,000 dentists in the United States can help source, advise, and invest in the most promising dental health innovations.

“With innovations in alignment, 3D-printed implants, and high-resolution imaging–to name a few–the time is right to welcome dental professionals into the AngelMD network,” said Tobin Arthur, AngelMD CEO. “We are already seeing traction with dental-focused startups, so adding the expertise of practicing dentists will help us to find and assist the companies that have real clinical promise.”

The AngelMD network is already home to thousands of physicians who offer their time, expertise, and investment dollars to help drive the future of healthcare. The dental community on AngelMD will play an equally critical role in identifying startups, scoring those companies on their clinical importance, and making syndicate investments with their colleagues.

The AngelMD investment team sees a significant opportunity for early acquisitions of startups in the dental market. The industry as a whole is looking to fuel its growth in this highly-competitive segment, with applications ranging from hospitals to clinics, and home use as well. Based on the best available data, AngelMD expects the dental consumables and equipment markets to see a combined annual growth rate in excess of 15 percent over the next five years.

For more information, or to register as a dentist on AngelMD, please visit

Continue reading

AngelMD Investor Group Closes Funding Round in HeartHero

Today, a group of AngelMD network investors is proud to announce its investment into HeartHero. HeartHero is a Denver-based company that has developed a smaller and lighter automated external defibrillator (AED) to increase the survivability of sudden cardiac arrest (SCA). The AngelMD syndicate has invested over $500,000 into HeartHero’s oversubscribed Series A round of funding.

SCA claims over 350,000 lives each year in the United States alone. For every minute that an SCA patient goes untreated, their survival chances drop by up to ten percent. AED intervention dramatically increases the patient’s chances of survival, but AEDs are widely unavailable outside of a hospital or professional setting.

“AngelMD’s investment and physician network is proof that a better outcome is wanted for Cardiac Arrest,” said HeartHero CEO Gary Montague. “They have been pivotal in helping us increase our reach with partners and opening doors to accelerate our company to save lives sooner. These connections would have otherwise been challenging to make, and for this, we couldn’t ask for a better partner.”

At half the size and weight of AEDs currently on the market and using standard consumer batteries, the HeartHero AED can be carried easily or stored at home by people at an increased risk of sudden cardiac arrest or their family. The HeartHero device guides the user through the resuscitation process with CPR prompts along with an auditory and visual guide.

“The portability and affordability of the HeartHero AED will save lives. By decreasing the time to life-saving defibrillation is how Elliot will improve the outcomes of sudden cardiac arrest,” said Dr. Bill Quirk, emergency room physician and HeartHero Chief Medical Officer. “We believe death from SCA is preventable. Our AED will empower family members and good samaritans to treat the #1 cause of death in the USA. The Resuscitation Revolution is here. HeartHero is excited to develop and deploy key tools in the chain of survival with our partners at AngelMD. Together we will save lives.”

The AngelMD syndicate investment follows HeartHero’s recent string of successes. The company was named as the winner of the American College of Cardiology’s Innovation Challenge pitch competition, as well as the American College of Emergency Physicians innovatED Innovation Challenge.

Continue reading

AngelMD Portfolio Company Saranas Awarded FDA De Novo Designation

The ultimate goal of AngelMD is to facilitate improved outcomes for startups, investors, and ultimately for patients. Today we are proud to share the news that Saranas, an AngelMD portfolio company, has obtained FDA clearance for its Early Bird Bleed Monitoring system. 

A recent study of over 17,000 large-bore transcatheter interventions showed that nearly one in five patients experience a bleeding-related complication. Saranas’ novel early-detection system addresses an unmet need for real-time detection and monitoring of these problems. The company’s last funding raise, in which AngelMD was also a proud investor, allowed for Saranas to submit the De Novo application to the FDA and launch a multi center clinical pilot within the United States.

Saranas originated from the Texas Heart Institute at the Texas Medical Center. Its goal is to provide real-time monitoring without the need for radiation, and at a lower cost than the status quo. 

The Early Bird Bleed Monitoring System is now being piloted across multiple centers to assess its versatility, and to increase patient safety. The company plans to launch the system commercially in selected centers across the US.

Continue reading

AngelMD Portfolio Company Raydiant Oximetry Awarded FDA Breakthrough Device Status

In the United States, roughly one out of every three babies born in the United States are delivered via cesarean section. According to key stakeholders, nearly half of these c-section deliveries are medically unnecessary. These major surgeries carry risks such as postpartum hemorrhage, rupture of the uterus, cardiac arrest, infection, complications from anesthesia, and much more.

Raydiant Oximetry, Inc. is a California-based company that has developed a safe and noninvasive technology that directly monitors a baby’s oxygenation during pregnancy. For clinicians who are dissatisfied with the lack of tools available to assess the baby during childbirth, this technology will lead to improved decision making and better care to mother and baby. Today, the company is announcing that it has been awarded Breakthrough Device status by the Food and Drug Administration (FDA).

“The FDA’s approval for a Breakthrough Medical Device status is an incredible validation for the work that we are doing,” said Raydiant Oximetry CEO Dr. Neil P. Ray. “Not only does it accelerate the path towards FDA approval, it’s also a public health validation that what we have been developing is a global priority for the health of mothers and babies.”

Shape the Future of Healthcare – Join AngelMD Today

The FDA’s Breakthrough program is targeted towards medical devices that address significant unmet clinical needs. It provides an expedited pathway to approval for market access. This pathway affords the sponsor a priority review with senior personnel and less pre-market clinical data for expedited approval.

“It is baffling that the public outcry over our current c-section rate isn’t louder than it is,” said AngelMD Lead Investor Dr. Wendy Whittington. “Raydiant’s new breakthrough status confirms that safe, effective tools to give doctors better information about in utero well being are necessary and timely. Tools to enable doing the right thing are welcome and necessary in this pivotal time for our healthcare system.”

AngelMD announced in September 2018 that a group of its investors had completed a funding round in Raydiant Oximetry. The company is now working on building its next generation prototype, to improve accuracy and reliability, which is slated for completion in February of 2019.

Continue reading